Results 111 to 120 of about 10,848 (199)

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas

BMJ Open
Introduction Relapses in ANCA-associated vasculitis (AAV) increase the incidence of end-organ damage and their prevention requires prolonged immunosuppressive therapy.
D. McGovern, Mark E. McClure, Matthew L. Coates, Simon Bond, Marcos Martinez del Pero, K. Mynard, Jacinta Lee, Rona M. Smith, David R. W. Jayne, M. Clatworthy, R. Jones   +10 more
semanticscholar   +1 more source

Obinutuzumab-induced Acute Thrombocytopenia Mimicking Immune Thrombocytopenia in a Patient with Follicular Lymphoma

Internal medicine
Obinutuzumab-induced acute thrombocytopenia is characterized by a rapid decrease in the platelet count after administration. The underlying mechanisms remain unclear. However, we present novel laboratory findings related to its pathophysiology. A 65-year-
Misato Tane, Hiroki Hosoi, T. Hiroi, S. Murata, T. Mushino, T. Sonoki   +5 more
semanticscholar   +1 more source

Obinutuzumab, an Anti-CD20, in Refractory Adult Autoimmune Podocytopathies: Report of 2 Cases

Kidney Medicine
Autoimmune podocytopathies can represent a therapeutic challenge in the case of frequently relapsing nephrotic syndrome leading to steroid dependence or steroid resistance.
T. Loeffler, A. Flahault, A. Alla, L. Frimat, R. Kormann   +4 more
semanticscholar   +1 more source

Obinutuzumab in kidney transplantation: Past, present, and future

World journal of transplantation
Antibody-mediated rejection (ABMR) and recurrent primary renal disease (PRD) represent major causes of kidney transplant (KT) loss. The standard of care for desensitization, ABMR, and relapsing autoimmune glomerulopathies or nephrotic syndrome includes ...
E. Favi, Marika Morabito
semanticscholar   +1 more source

Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.

The Lancet Haematology
BACKGROUND Triplet regimens combining a Bruton's tyrosine kinase inhibitor, B-cell lymphoma 2 inhibitor, and anti-CD20 antibody are among the most effective first-line treatments for chronic lymphocytic leukaemia, but come with substantial toxicity.
A. Kater, S. Kersting, J. Dubois, B. van der Holt, C. da Cunha-Bang, Doreen G. Te Raa, Cecile A. M. Idink, F. de Boer, J. Droogendijk, K. de Heer, L. van der Burg, M. R. Nijziel, L. Tick, H. Levenga, Matthijs Silbermann, I. Ludwig, A. Beeker, M. Bellido, J. Dobber, L. Evers, A. F. van der Kevie-Kersemaekers, C. Mellink, Ine Meulendijks, S. Cunha, M. Abrahamse-Testroote, G. Zwezerijnen, J. Zijlstra, C. Niemann, M. Levin   +28 more
semanticscholar   +1 more source

Obinutuzumab in hematologic malignancies: Lessons learned to date.

, 2015
The routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in CD20-positive non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Klein, Christian, Davies, Andrew, Gilles Salles, Sehn, Laurie H, Cartron, Guillaume, Illidge, Tim; id_orcid, Salles, Gilles, Sehn, Laurie, Tim Illidge, Laurie H. Sehn, Guillaume Cartron, Christian Klein, Illidge, Tim, Andrew Davies, Davies, A, Salles, G, Illidge, Timothy M, Klein, C, Sehn, L, Cartron, G   +19 more
core   +1 more source

A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma

Blood Advances
Key Points • For patients with untreated high tumor burden follicular lymphoma, obinutuzumab and lenalidomide led to a 2-year PFS rate of 93.3%.• Obinutuzumab combined with lenalidomide was well tolerated with the most common AEs being diarrhea, rash ...
Neha Akkad, Lei Feng, J. Westin, F. Hagemeister, Hun Lee, L. Fayad, Sairah Ahmed, R. Nair, M. Rodriguez, P. Strati, D. Chihara, C. Flowers, Linda Claret, K. Ibanez, Michael L. Wang, N. Fowler, J. Henderson, R. Davis, S. Neelapu, M. R. Green, L. Nastoupil   +20 more
semanticscholar   +1 more source

Safety of Obinutuzumab in Children With Autoimmune Encephalitis and Early B-Cell Repopulation on Rituximab

International audienceOBJECTIVEThe study objective was to report the use and safety of obinutuzumab in rituximab-resistant children with neurological inflammatory diseases.METHODSThis study was a single-center retrospective cohort study about all the ...
Cisternino, Salvatore, Sarda, Eugénie, Bustamante, Jacinta, Mesples, Bettina, Fayard, Claire, Aubart, Mélodie, Nguyen, Ai-Tien, Gins, Clarisse, Cotteret, Camille, Durrleman, Chloé, Desguerre, Isabelle   +10 more
core   +1 more source

Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome

Journal of Clinical Medicine
Background: Idiopathic nephrotic syndrome (INS) is the most common cause of nephrotic syndrome in children. A hallmark of the disease is the rapid remission of proteinuria following a high dose of steroids.
M. Drozynska-Duklas, Anna Kranz, I. Zagożdżon, I. Balasz-Chmielewska, I. Chudzik, A. Żurowska   +5 more
semanticscholar   +1 more source

Acute obinutuzumab-induced thrombocytopenia in follicular lymphoma: case report and literature review

Frontiers in Oncology
Introduction Obinutuzumab, a type II anti-CD20 monoclonal antibody used in the treatment of follicular lymphoma, is associated with a higher incidence of adverse events, including thrombocytopenia, compared to rituximab. We report a case of severe, acute
Jie-Yi Zhou, Miao Chen, Yi Zhang, Ce Xu, Rong Li   +4 more
semanticscholar   +1 more source